Crossmark

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Crossref DOI link: https://doi.org/10.1016/S1473-3099(23)00184-6

Published Print: 2023-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Kaye, Keith S

Shorr, Andrew F

Wunderink, Richard G

Du, Bin

Poirier, Gabrielle E

Rana, Khurram

Miller, Alita

Lewis, Drew

O'Donnell, John

Chen, Lan

Reinhart, Harald

Srinivasan, Subasree

Isaacs, Robin

Altarac, David
License Information

Text and Data Mining valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01

stm-asf valid from 2023-09-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Journal Title: The Lancet Infectious Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1473-3099(23)00184-6

CrossRef DOI link to the associated document: https://doi.org/10.1016/S1473-3099(23)00203-7

Content Type: article

Copyright: © 2023 Elsevier Ltd. All rights reserved.

Document is current

Any future updates will be listed below